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Background: Shared decision-making in rheumatoid arthritis (RA) care is a priority among policy makers, clinicians
and patients both nationally and internationally. Demands on patients to have basic knowledge of RA, treatment
options, and details of risk and benefit when making medication decisions with clinicians can be overwhelming,
especially for those with limited literacy or limited English language proficiency. The objective of this study is to
describe the development of a medication choice decision aid for patients with rheumatoid arthritis (RA) in three
languages using low literacy principles.
Methods: Based on the development of a diabetes decision aid, the RA decision aid (RA Choice) was developed
through a collaborative process involving patients, clinicians, designers, decision-aid and health literacy experts. A
combination of evidence synthesis and direct observation of clinician-patient interactions generated content and
guided an iterative process of prototype development.
Results: Three iterations of RA Choice were developed and field-tested before completion. The final tool organized
data using icons and plain language for 12 RA medications across 5 issues: frequency of administration, time to
onset, cost, side effects, and special considerations. The tool successfully created a conversation between clinician
and patient, and garnered high acceptability from clinicians.
Conclusions: The process of collaboratively developing an RA decision aid designed to promote shared decision
making resulted in a graphically-enhanced, low literacy tool. The use of RA Choice in the clinical encounter has the
potential to enhance communication for RA patients, including those with limited health literacy and limited English
language proficiency.
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Significant advances have been made in treatment options
and strategies for rheumatoid arthritis (RA), one of the
most common forms of inflammatory arthritis. These
advances have shifted the goal of therapy from symptom
relief to sustained remission. Over the past twenty* Correspondence: Jennifer.Barton@va.gov
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unless otherwise stated.years, 10 new disease-modifying anti-rheumatic drugs
(DMARDs) have been approved by the FDA for use in
RA. These innovations have improved outcomes, but
introduced high complexity for patients and clinicians
when making treatment decisions about individual
agents and their use in combination. Like the treatment
of many other chronic diseases, adherence to biologic
DMARDs can be poor with persistence rates ranging
from 42-71% [1].
Despite advances in therapy, variation in outcomes
persists, with certain populations experiencing poorerThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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white, immigrants, or who have limited English language
proficiency have been found to have higher disease activity
and poorer function despite access to effective therapies
[4]. In addition, limited health literacy has also been
associated with greater disability [5]. We define health
literacy using the Affordable Care Act of 2010 defin-
ition: “the degree to which an individual has the cap-
acity to obtain, communicate, process, and understand
basic health information and services to make appropriate
health decisions”. One potential mechanism for persistent
variation in outcomes is variation in the interpersonal pro-
cesses of care, such as patient-provider communication.
We have found that nearly one-third of adults with RA
report suboptimal shared decision-making (SDM) com-
munication. Patients with lower education, limited health
literacy, lower trust in physician and limited English
language proficiency are more likely to report suboptimal
SDM [6].
Shared decision-making in RA care is a priority among
policy makers, clinicians and patients both nationally
and internationally [7-10]. The demands on patients to
have a basic level of knowledge of RA, the therapeutic
options, and details of safety and efficacy of treatments
when making a decision with their clinicians can be
overwhelming, especially for those with barriers to
communication like literacy or language. Competing
tasks place clinicians at a disadvantage as they may not
find time to inform patients of treatment options, dis-
cuss benefits and harms, and engage patients in shared
decision-making.
Taking into account these increasing demands on pa-
tients and clinicians, evidence of suboptimal SDM, and
disparities in outcomes, we set out to design a decision
aid for use in the clinical encounter to facilitate conver-
sation between patients and clinicians around issues
related to RA medications. Here we describe and discuss
lessons learned in the development of the decision aid.
We based the RA decision aid development on a
process used to design a tool for patients with diabetes
[11] which has been shown to enhance knowledge and
improve patient involvement in decisions [12]. Breslin
et al. noted that the shared decision-making model for
patients with chronic disease must begin with partner-
ship building, sharing of information, shared deliberation
and, ultimately, joint decision making. They observed
that patients make decisions about medications after
leaving the clinician’s office, without the opportunity to
ask questions, state their preferences or air concerns
about medications. The motivation behind the diabetes
decision aid design was to encourage patients to share
concerns, raise issues, and ask questions during the
encounter such that patient and clinician could arrive at
a decision together. In this manner, clinicians could gaina shared understanding of the patient’s preferences,
values, and context, and patients could make decisions
about starting and using medicines informed by the
clinician’s experience and expertise. Therefore, the goal
of this project was to use a collaborative user-centered
design process to create a tool, the RA decision aid, to
facilitate patient engagement when choosing a new
DMARD. Given the disparities in RA outcomes [2-4]
and reports of poor shared decision-making commu-
nication among vulnerable populations, we chose to
develop our tools for those with limited health literacy
and include non-English languages of Spanish and Chinese.
The concept of health literacy was addressed in the RA
decision aid by following guidelines for developing low
literacy materials (e.g., use of icons, plain language,
more white space) as well as including patients of all
literacy levels in the development process, and creating
a tool that focused less on reading and more on conver-
sation and verbal exchange of information. We adopted
a collaborative approach, sometimes referred as partici-
patory action research [13], to develop the decision aid.
This process involves patients and clinicians – the users
– at every step of the process, as well as experts in the
development of decision aids, health literacy, and de-
signers to translate the materials into a tool that users
would want to use.
Methods
Overview
Given that the majority of patients newly diagnosed with
RA are started on methotrexate [14,15], we created our
tool for the clinical context of an established RA patient
with moderate to high disease activity who, at a mini-
mum, has failed a trial of methotrexate. A 2013 study
reported on the non-inferiority of triple combination
synthetic DMARD therapy compared to adding a biologic
[15] to methotrexate such that there is no one algorithm
to direct medication choice in RA. At the time of the
decision aid development, twelve DMARDs (4 synthetic
and 8 biologic DMARDs) had been approved by the
FDA and were commonly used in practice. While there
are more than 12 FDA-approved DMARDs for RA,
several are very rarely used in clinical practice.
The research protocol for this study was approved by
the UCSF Committee on Human Research (IRB Number:
10-02339). All patient participants gave their written
informed consent to be part of the study. All individuals
whose images appear in the guide (Figure 1) signed
written consent for permission to use their images for
the purposes of the guide (research and education).
The team
Using the design of the diabetes issue cards as a guide, we
convened a diverse group of individuals with expertise in
Figure 1 Cover of the patient education material, “your guide to rheumatoid arthritis medications”, and two-page spread of
chapter 1: “What is rheumatoid arthritis?”.
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design (TM, MB, DR), health literacy (JA, DS), clinical
and qualitative research methods (LT, EY, CJK). We
adopted the design approach described by Breslin et al.
and encouraged all members of the team to bring meth-
odologies and ideas from their respective fields to the
table. This approach, with foundations in the design
discipline, draws upon elements of field ethnography
(which involves direct observation in clinic about how
patients and clinicians discuss treatments) as well as
participatory action research where both patients and
clinicians contribute to the research by allowing partici-
pant observers (or third party researchers) to observe
actual clinic visits. In addition, patients contributed by
informing the researchers about content of the decision
aid and evaluating prototypes both on an individual
basis in cognitive interviews and as a larger group in a
patient advisory board. Results from the cognitive inter-
views fed back directly into decisions regarding design,
number of issue cards, and as a factor in how many
cards were ultimately included in the final deck. Con-
tent from the interviews was discussed in team meet-
ings and phone calls with consultants and designers.
Patients participated in two ways. The first was to
invite patients from several previously conducted focus
groups (one each in English, Spanish or Cantonese led
by a bilingual, trained focus group moderator using a
common interview guide that had been translated) to sit
on a patient advisory board which met approximately
every two months during the 18-month-long develop-
ment process. The purpose of the initial focus groups
was to gather data to inform the content and delivery of
an adapted medication summary guide for RA medica-
tions as well as to explore patients’ perspectives on
participation in decision making with their clinicians.
The Grounded Theory Method [16] using constant com-
parison to determine similarity and differences within
and between groups was used to analyze the transcripts
[17]. We recruited heavily from the county hospital
clinic for the focus groups, of whom over half had high
school education or less. We then selected members for
the board who had a range of literacy and education levels
and continually emphasized the low literacy principles for
the tool development. Of 9 board members, one-third
had limited health literacy. The common language was
English; however, several members were bilingual (either
in Spanish or Cantonese). Cantonese, not Mandarin, is the
predominant language spoken by Chinese speakers in San
Francisco. Patients also participated during clinic visits at
one of two clinics, the university-hospital based arthritis
clinic or the county-hospital based RA clinic, when the
prototypes were being tested. Clinical rheumatologists
provided input as they tested the prototypes in clinic
and offered feedback in research meetings.The development process
In addition to using the diabetes issue cards as a
template, we followed six steps for the development of
low literacy materials outlined by Seligman et al. [18]
where the authors describe a process whose main
purpose is to create materials which will increase
knowledge as well as activate low literacy patients
toward healthier behaviors. The six steps are presented
in Table 1. Seligman et al. underscore the importance of
mapping concepts onto a behavioral theory, such as the
social cognitive theory, which suggests that materials
should improve knowledge, positively influence out-
come expectations, emphasize facilitators of behavior
change, address barriers to behavior change, and facilitate
the creation of goals [19].
The funder of this project, the Agency for Healthcare
Research and Quality (AHRQ), published a summary of
their comparative effectiveness review of RA medica-
tions for patients and clinicians [20,21]. Results from
this review were used as the basis of the literature re-
view for the decision aid. Additional systematic reviews
of DMARDs and classes of DMARDs [22-25] were used
to supplement the AHRQ review. In addition to gathering
evidence-based reviews on DMARD safety, tolerability
and comparative effectiveness, we also collected data on
how medication discussions were taking place in clinics,
as well as eliciting patient concerns about starting a new
medication in focus groups, cognitive interviews, and from
the advisory board. The process of combining data from
the evidence synthesis and direct observations with feed-
back from various stakeholders is illustrated in Figure 2.
The development team reviewed and discussed issues
that emerged from the literature review, clinical observa-
tions, and patient comments, and began to create proto-
types of the cards. Each card was devoted to a particular
issue, such as “side effects” or “cost” as based on the
diabetes card design. The number, content, and design
of the cards varied throughout their development. Clini-
cians were asked to use prototypes in clinical encounters
where a third party (GEY) observed and recorded how
the tool was used, the content of conversations around
medications, and the level of patient involvement in the
encounter. Prototypes were evaluated in recorded one-
on-one interviews with a member of the research staff
(LT, JB) and RA patients, as well as non-RA patients
(in role play) to gather insights into the content and
design of the tool and its ability to generate a conversa-
tion. Mock clinic visits and actual clinic visits using the
prototypes were then observed by the designer (TM)
and other team members (LT, GEY) after which they
provided feedback on the nature of the conversations.
Health literacy experts also reviewed the prototypes.
In discussions with the patient advisory board, we
sought to identify any issues that the cards did not cover
Table 1 Six steps for developing low literacy educational materials
Key concept Study phase





2. Identify key concepts to be communicated Focus groups provide feedback on main areas of content:
• Broad category of medicines for RA
• Benefits of DMARDs across mono- and combination therapies
• Talking with the doctor about RA drugs
• Learning about risks
• Ways to reduce risk
• Cost
3. Map concepts to a behavioral theory, such as social cognitive theory
and construct a brief intervention to support the use of written materials
Phase 1 -social cognitive theory suggests that materials should:
• improve knowledge
• positively influence outcome expectations
• emphasize facilitators of behavior change
• address impediments to behavior change
• facilitate the creation of goals
4. Carefully design materials using low-literacy principles Phase 2: adopt AHRQ summary guide for low literate, limited
English language proficient patients
• Use illustrations
• ≥ 14 pt font
• Adequate white space
5. Refine materials using input from the target population Phase 2
• In-depth, semi-structured interviews
• Review adapted guides with patient advisory board
6. Assess success of efforts in target audience and learn from failures Phase 3 – pilot test of decision aid, evaluate acceptability and
outcomes of knowledge and decisional conflict
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importantly, we examined whether the cards accom-
plished the goal of creating a conversation between
patient and clinician. Iterations of the tool continued
until the main patient issues and concerns were coveredFigure 2 Iterative process of the RA choice decision aid
development. Figure adapted from LeBlanc et al. [26] with permission.and the cards were consistently generating an exchange
between clinician and patient about RA medications. This
entire process took approximately eighteen months.
Role of the funding source
AHRQ funded this project and played no other role in
this work.
Results
Developing the decision aid
Content
The content was derived from the AHRQ and other
evidence-based reviews as depicted in Figure 2. The
DMARDs presented in the original AHRQ summary
guide included anakinra which upon discussions with local
rheumatologists was deemed to be used exceedingly rarely
in the treatment of adult RA. Therefore, anakinra was
not included. A total of twelve DMARDs were included:
synthetic DMARDs - hydroxychloroquine, leflunomide,
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cept, adalimumab, certolizumab, etanercept, golimumab,
infliximab, rituximab, tocilizumab. The newest FDA-
approved DMARD for RA, tofacitinib [27], received its
approval after development was completed and is not
included.
Route of administration, frequency of dosing, and side
effects vary among DMARDs and play a role in patient
preferences for choosing an RA medication [28-33].
Other important patient issues that emerged in focus
groups, advisory board meetings and in clinical encoun-
ters included cost, benefits, and time until clinical effects
are experienced. Clinician concerns included special
considerations such as pregnancy (some DMARDs are
teratogenic), latent or active tuberculosis (all biologic
therapies increase the risk for opportunistic infections
including TB), and alcohol consumption (methotrexate
and leflunomide can be hepatotoxic; heavy alcohol con-
sumption is contraindicated). Clinicians aware of the
benefits of combination therapy using two or more
DMARDs to achieve greater efficacy were interested in a
combination DMARD issue card as well as one which
would address goals of therapy for RA.
Form and information design
The team decided a priori to use the issue card format
developed by Breslin and colleagues at the Mayo Clinic.
Therefore, our prototypes varied over time in the number
of issue cards in each “deck”, and the design and content
of each card. At three distinct time-points we had a
collection of cards which varied by number and appear-
ance, as discussed below.
First prototype deck
Our initial set of cards consisted of six issues: medica-
tion routine, cost, results (time to onset), side effects, in-
fection risks, and special considerations. Ten medications
(methotrexate and rituximab were not initially included)
were organized with pills on one card and then IV/sub-
cutaneous injectables on another. We then combined all
medications onto one card in a consistent way across all
issues grouping them by mode of administration: oral,
subcutaneous (“shots under the skin”) and intravenous
delivery (“given in the vein”). Following low literacy princi-
ples to use more illustrations, the research team explored
the use of images: photographs of pills, a person giving
himself an injection, and an arm with an IV as well as
cartoons or icons.
We elicited feedback from a group of rheumatologists
and from the patient advisory board on this first iter-
ation. Physicians overall were concerned that the cards
“may open a can of worms” and prolong the length of
the clinical encounter, however they felt certain cards
(like the “routine” card) were very important. Specificclinician feedback included suggestions to add icons for
pills/IV/subcutaneous injections; separate common from
rare and mild from severe side effects; and add a “benefits”
card to show efficacy. Clinicians emphasized that they
often have their own order in which they present medica-
tion options (e.g., 1st line, second line, third, etc.) and were
concerned that patients may interpret the order in which
the medications are listed on the cards as an order of
preference. Physicians felt that the cost issue was very
individualized depending on patient insurance and that
it may be more important to first make the decision
regarding which medication and then deal with cost.
Also, they were concerned that patients may perceive
this card in a negative way, as in: “why should we care
about costs?” Clinician concerns around cost were
misaligned with those of patients who expressed inter-
est and concern about medication cost in focus groups
and during prototype reviews. One Cantonese-speaking
patient upon seeing the actual costs of a biologic
commented: “If you want me to pay, I prefer to die.
Where can I get the money?”
Patient advisory board members piloted the cards
using role play with one another and two researchers
(GEY, LT). During this exercise, several patients took on
the role of a patient and the other a doctor while a third
party observed the conversation. Elicitation of values
and concerns were observed during the use of the cards,
cost was discussed frequently as was mode of adminis-
tration and onset of action. No issue cards were felt to
be missing from the discussion though one patient
wanted to see prednisone (which is not traditionally
considered a DMARD) on the cards.
The designers then piloted three different visual de-
signs (Figure 3).
Second prototype – deck #2
The research team and designers, with feedback from
the patient advisory board, selected their preferred font,
colors, icons, and layout for a consistent visual presenta-
tion in this next iteration (Figure 4). In addition to the
design revision, a “benefits” or efficacy card was added
in response to feedback, and infection risk was incorpo-
rated into the side effects card. For the benefits card, the
research team chose to use pictographs to illustrate
efficacy given a growing body of evidence showing that
pictographs are more quickly and better understood
than other graphical formats [34]. The benefits card
illustrated the number of people out of 100 who achieve
an American College of Rheumatology (ACR) 50 re-
sponse which reflects a 50% improvement in tender and
swollen joints and 3 of 5 additional criteria [35] to each
of the listed medications. This is a standard measure of
efficacy included in RA clinical trials and data for this
domain was extracted from the literature review.
Figure 3 First iteration of the issue cards. Note the variation in the size of text, fonts, use of icons, and organization of medication names.
Six issue cards were included in this “deck”: routine, cost (as seen above), results (onset of action), side effects, infection risk and special issues.
(A) Design 1, (B) Design 2, (C) Design 3.
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additional cards: mode of administration, combination
therapy, and goals. The “mode” card (Figure 5a) illustrated
route of administration using icons of a pill, a pre-filled
syringe and an infusion bag with tubing and needle as well
as icons of a home and clinic/hospital to depict the setting.
The combination therapy card (Figure 5b) came out of
discussions with clinicians who are aware of the evidence
that combination therapy of a synthetic DMARD such
as methotrexate with a biologic has superior efficacy
than monotherapy with either agent [36]. This is also
true of combination therapy with synthetic DMARDs
(e.g., triple therapy with methotrexate, hydroxychloro-
quine and sulfasalazine) [37]. Clinicians and the research
team also felt that prior to initiating a discussion of the
issue cards with a patient, clinician and patient goals for
therapy be established. Goal concordance between patient
and provider has been shown to lead to better outcomes
in other chronic diseases [38,39]. This prompted the
prototype of a “goals” card (Figure 5c).
Final decision aid tool – deck #3
Several changes were made to this final deck in response
to feedback from multiple stakeholders. Clinicians wereextremely concerned about the amount of time it would
take to review all eight issue cards (including the goals
and combination therapy card) however they did note
that the cards pushed them to consider patient prefer-
ence as well as their own which they acknowledged pro-
moted patient-centered care (their default was to tell the
patient which drug they preferred, as opposed to elicit-
ing patient preferences; the cards helped initiate that
conversation). Patients reported some difficulty reading
lighter color text on top of color, but liked the icons and
calendar depictions. In cognitive interviews, it became
clear that the goals card generated tangential conversa-
tions which distracted patients and providers from the
task at hand. The combination card did not add to the
conversations and it was deemed by our decision aid
expert to be a “doctor” card in that it was information
the doctor could easily convey in a sentence and was not
an issue of importance to the patient. With respect to
time, visits during the initial prototype testing varied from
30 to 60 minutes. We attributed some of this to a lengthy
introduction of the tool to patients as well as a greater
number of issue cards in the deck (Deck #2 - 8 cards).
Three cards were then eliminated from the deck (goals,
benefits, combination therapy) and a more stream-lined
Figure 4 Second iteration of issue cards. This deck included one new issue card on benefits, and collapsed the infection risk card into the side
effect card for a total of six cards: (A) benefits, (B) considerations (special issues), (C) cost, (D) results, (E) routine, (F) side effects.
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Figure 5 Three issue cards added to deck #2 based on clinician feedback: Mode of administration, combination therapy, and goals of
therapy. A. Mode of administration prototype. B. Prototype of combination therapy issue card. C. Prototype of goals issue card.
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With these adjustments, visit length on average was 33 -
minutes (range 12-57 minutes) and often did not take
longer than a visit without the tool. One user reported an
increase visit time of 2 minutes with the tool. Clinicians
were asked to start the conversation about choosing a
medication with three main issue cards (how often, how
soon and cost), and if patients asked questions about side
effects or raised concerns related to special considerations,
those cards would be pulled into the conversation. Thus
the team arrived at a final set of five issue cards to be used
in the clinical encounter (Figure 6). The final tool was
translated and back-translated [40] into Spanish and
Chinese by a professional translation agency (Figure 7).
Discussion and conclusion
Discussion
The development of a low literacy medication decision
aid (RA Choice) in three languages was feasible using a
collaborative process with patient and clinician input at
every step. There is a clear need for increased support
and structure to promote and facilitate shared decision-
making in RA, especially among more vulnerable popu-
lations with poorer health outcomes and barriers to
communication like literacy and language. Decision aidsare one way to promote patient-centered care [41].
There are several decision aids for patients with RA
[42-44], however none have been developed for patients
with limited health literacy or limited English language
proficiency for use in the clinic encounter.
During our development process, certain decisions
had to be made to respect clinician concerns about
consultation time, inability to have comprehensive infor-
mation on the cards and meet standards for a low liter-
acy tool, and be cognizant of not overwhelming patients
with too much information. We based our tool develop-
ment on a process described for a diabetes decision aid,
the overarching goal of which was to create a conversa-
tion between patients and clinicians. Both diabetes and
RA are chronic conditions with multiple options for
therapy requiring a high degree of self-management.
Given the parallels between the two conditions and
choices for therapy, the diabetes issue card design was
an excellent template for the RA decision aid.
Our process was not without limitations. While we
created the decision aid and translated (and back-
translated) it into Spanish and Chinese, we found it
difficult to fully involve Cantonese-speaking patients and
research staff in the process. Due to time constraints we
were unable to thoroughly pilot the tools with Cantonese
Figure 6 Final set of five issue cards and a cover page (F) for a tri-fold copy of the cards given to patients at the end of their clinic
visit. (A) Considerations, (B) Cost, (C), How Soon?, (D) How Often?, (E) cover page, (F) Side Effects.
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Figure 7 Illustration of the special considerations issue card in each of the three languages: (A) English, (B) Spanish and (C) Chinese.
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are both language and cultural adaptions which may
enhance the use and efficacy of RA Choice given the
opportunity to observe a broader number of encounters
and this is a goal for future projects. More specifically,
lessons learned for future work include a focus on a single
language during development, more in depth cognitive
interviews with Cantonese speakers, and to determine the
best way, without using names or characters, to share
information on medications (of note, only one of 7
Cantonese focus group participants could recognize the
written name of their RA medications and relied on color
and size of pill). In addition, background research on
shared decision making preferences in these populations
is needed. We chose to create a print tool (as opposed to
web-based) which may limit its usability in clinics which
are fully electronic, as well as limit, if effective, our ability
to distribute it and keep it up-to-date without having to
recall distributed cards. It may also make it more difficult
to keep the tool updated with new medications or com-
parative effectiveness data. A web-based version of the
tool may be more appropriate once exam rooms are better
equipped for full participation of patients and providers
and the investment justified by evidence of efficacy of the
cards. It is also a challenge to create a design that appeals
to all users, therefore an electronic tool tailored to eachindividual may have greater reach as well as be easier to
update. The state of the comparative effectiveness litera-
ture made it impossible to accurately depict benefits (lack
of head to head trials for all biologics) and the research
team ultimately concluded that using a measure such as
the ACR 50 misled patients (i.e., depicting one medicine
as more effective, leading to more patients achieving an
ACR 50, when head-to-head trials are either not available
or suggest no difference). This led to a decision not to
include an issue card on efficacy. The complete experience
of the decision aid tool in the clinical encounter relies on
the communication skills of the clinician to engage the
patient in conversation and of the patient to engage in
conversation and for both to use the tools as intended. In
contrast to the development of the diabetes decision aid,
we were not able to pilot test the cards in actual clinical
encounters in high numbers consistently across the tool
development (more so in the beginning stages) due to the
fact that clinics would be sites for a pilot trial.
The tool, in and of itself, does not meet all International
Patient Decision Aid Standards (IPDAS) Collaboration
criteria, which were designed for standalone tools directed
at patients. However, cumulative, including through
this publication, the tool satisfies criteria for balanced
evidence-based and up-to-date information, depiction
of relevant issues using state-of-the-art approaches, and
Barton et al. BMC Medical Informatics and Decision Making  (2014) 14:104 Page 12 of 14designed for purpose and setting [45]. The categories of
the IPDAS criteria that were not met include: a descrip-
tion of the positive features (as discussed above a benefits
issue card is not included in the deck), presentation of
probabilities of outcomes (to do so would have added
significant complexity to the design of the tool which in
turn would create excess burden on patients with limited
health literacy). In terms of values clarification, this takes
place upon the introduction of the issue cards by the
clinician when he or she asks the patient to “pick which
issue you would like to discuss first” about a new medica-
tion. The act of allowing the patient to hold and select an
issue card is a concrete way to allow the patient to clarify
and express his or her values. By providing a copy of the
decision aid in the form of a trifold pamphlet as well as
the medication summary guide to take home, patients are
also encouraged to share with family or friends what may
matter most to them in choosing a medication – be it
cost, mode of administration, side effects, etc.
Conclusion
The development of a low literacy decision aid for RA
medications in three languages was feasible using a
collaborative process with patient, clinician and design
input. Our decision aid, which is intended to be used in
the context of an RA patient with moderate to high
disease activity despite being on at least one DMARD,
promoted a conversation and exchange of experience
on the part of the clinician and values and preferences
on the part of the patient. It is our expectation that the
use of RA Choice in the clinical encounter will foster
more patient-centered care and enhance shared decision-
making for all RA patients.
Practice implications
A clinical trial to test the final prototype of RA Choice is
needed to determine its impact on patients and clini-
cians, its feasibility for use in usual care settings, and its
impact on process and outcomes of care.
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